Fig. 4 | Genetics in Medicine

Fig. 4

From: Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review

Fig. 4

Risk ratios for severe neutropenia by UGT1A1 genotype from eight published studies.14,45–51 The studies are listed on the x-axis, stratified by heterozygote individuals (*1/*28) versus wild type (*1/*1) on the left-hand side and homozygote individuals (*28/*28) versus wild type on the right-hand side. Two results (Iyer 2002 for heterozygotes, Carlini 2005 for homozygotes) are not shown as the risk ratio could not be computed due to no observations in one or more groups. The bars indicate the 95% confidence interval (CI) with the consensus estimate (All) for the two comparison groups. The dotted line indicates a risk ratio of 1.00 (no difference). The two thin solid lines indicate the consensus estimates for the two groups of 1.82 (95% CI 1.16–2.85) and 3.51 (95% CI 2.03–6.07), respectively.

Back to article page